Working… Menu

Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03804944
Recruitment Status : Recruiting
First Posted : January 15, 2019
Last Update Posted : July 16, 2021
United States Department of Defense
Merck Sharp & Dohme Corp.
Celldex Therapeutics
Information provided by (Responsible Party):
Weill Medical College of Cornell University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2023